Drug intelligence / Profile preview

GS-9911 + zimberelimab

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

GS-9911 + zimberelimab is a combination therapy being investigated for advanced solid tumors. GS-9911 is an oral small molecule inhibitor of diacylglycerol kinase alpha (DGKα), targeting immune modulation and anti-tumor activity. Zimberelimab is an intravenously administered anti-programmed cell death protein 1 (PD-1) monoclonal antibody, acting as an immune checkpoint inhibitor to enhance T-cell mediated immune responses against cancer. The developer and sponsor for both drugs in this combination in clinical trials is Gilead Sciences. The main goal of current Phase 1 trials is to assess safety, tolerability, optimal dosing, and preliminary efficacy in adults with advanced solid tumors[1][3][5][7].

Other names: GS-US-521-6317GS-US521-6317GS-US 521-6317anti-PD-1 monoclonal antibodyanti-PD1 monoclonal antibodyanti-PD 1 monoclonal antibody

Targets

DGKA (Diacylglycerol kinase alpha)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GS-9911 + zimberelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-9911 + zimberelimab.

Explore the full profile